Azor Biotek is developing RNA-targeting small molecule therapeutics for the safe and curative treatment of neurodegenerative and pulmonary diseases. Our hit-to-lead flagship therapeutics are designed to target miR-29 with exquisite specificity and bioavailability dwarfing that of comparable oligonucleotides.